Swiss National Bank Has $5.58 Million Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Swiss National Bank increased its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 1.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 219,300 shares of the company’s stock after buying an additional 2,400 shares during the quarter. Swiss National Bank owned 0.12% of BridgeBio Pharma worth $5,583,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Frazier Life Sciences Management L.P. lifted its position in shares of BridgeBio Pharma by 6.4% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,632,604 shares of the company’s stock worth $92,014,000 after buying an additional 217,000 shares during the last quarter. Ensign Peak Advisors Inc lifted its position in shares of BridgeBio Pharma by 44.5% during the 2nd quarter. Ensign Peak Advisors Inc now owns 1,646,202 shares of the company’s stock worth $41,698,000 after buying an additional 506,845 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of BridgeBio Pharma by 40.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,534,972 shares of the company’s stock worth $38,881,000 after buying an additional 442,248 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of BridgeBio Pharma by 1.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company’s stock worth $29,155,000 after buying an additional 19,978 shares during the last quarter. Finally, Emerald Advisers LLC lifted its position in shares of BridgeBio Pharma by 65.6% during the 3rd quarter. Emerald Advisers LLC now owns 1,103,508 shares of the company’s stock worth $28,095,000 after buying an additional 437,164 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors.

Insider Buying and Selling at BridgeBio Pharma

In other news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $25.75, for a total value of $149,350,000.00. Following the transaction, the insider now owns 25,260,971 shares in the company, valued at $650,470,003.25. This trade represents a 18.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Brian C. Stephenson sold 4,156 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $93,135.96. Following the completion of the transaction, the chief financial officer now owns 93,758 shares in the company, valued at $2,101,116.78. This represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,831,545 shares of company stock valued at $150,056,923. Company insiders own 24.66% of the company’s stock.

BridgeBio Pharma Stock Performance

Shares of BridgeBio Pharma stock opened at $27.49 on Thursday. BridgeBio Pharma, Inc. has a 52 week low of $21.62 and a 52 week high of $44.32. The stock has a 50 day moving average price of $25.00 and a two-hundred day moving average price of $26.22. The stock has a market capitalization of $5.20 billion, a PE ratio of -11.41 and a beta of 1.09.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Bank of America increased their target price on BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday. JPMorgan Chase & Co. dropped their target price on BridgeBio Pharma from $46.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $70.00 target price on shares of BridgeBio Pharma in a research report on Monday, September 16th. Oppenheimer assumed coverage on BridgeBio Pharma in a research report on Thursday, October 3rd. They issued a “market perform” rating for the company. Finally, Leerink Partners dropped their target price on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.43.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.